Description

Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs)[1].–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Cancer-programmed cell death-Formula-C64H103N13O15-Citation–References-[1]Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.-CASNumber-2684216-48-4-MolecularWeight-1294.58-Compound Purity-99.84-SMILES-CC[C@@H]([C@H](N(C)C([C@@H](NC([C@@H](N(C)C(OCC1=CC=C(C=C1)NC([C@@H](NC([C@@H](NC(CNC(CNC(CN)=O)=O)=O)C(C)C)=O)CCCNC(N)=O)=O)=O)C(C)C)=O)C(C)C)=O)[C@H](OC)CC(N2[C@H]([C@H](OC)[C@H](C(N[C@@H]([C@H](C3=CC=CC=C3)O)C)=O)C)CCC2)=O)C-Research_Area-Cancer-Solubility-DMSO : 100 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related